Paroxysmal supraventricular tachycardia (PSVT)
Drug research and approvals for paroxysmal supraventricular tachycardia (PSVT): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 4 studies of paroxysmal supraventricular tachycardia (PSVT) are recruiting on ClinicalTrials.gov, and Health Canada has authorized 6 drug trials for it since 2013.
- Recruiting worldwide: 4
- Trials authorized in Canada: 6
- FDA orphan approvals: 0
- EU medicines: 0
- AI-Based Differential Diagnosis and Localization of Tachycardia Using ECG: Multicenter Registry (EP-AI ASSIST)NCT07859020 · Not reported · Inha University Hospital · starts Dec 1, 2023
- NASVAL-SVT: Nasal Swab Versus Modified Valsalva for Supraventricular TachycardiaNCT07617077 · Not applicable · Marmara University Pendik Training and Research Hospital · starts May 1, 2026
- Efficacy of Adenosine as Compared to Verapamil in Paroxysmal Supraventricular Tachycardia (pSVT) PatientsNCT06717685 · Phase 3 · Rashid Latif Medical College · starts Oct 28, 2024
- The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)NCT05763953 · Phase 2 · Milestone Pharmaceuticals Inc. · starts Dec 11, 2023
| Jun 11, 2026 | A randomized, double-blind trial of 12 mg versus 6 mg intravenous adenosine for the termination of paroxysmal supraventricular tachycardiaAdenosine | Dr. Seth Davis | Pending |
| Feb 8, 2024 | Multi-center, multi-national, open-label, efficacy and safety study of etripamil nasal spray in pediatric patients with paroxysmal supraventricular tachycardiaEtripamil (MSP-2017) | Milestone Pharmaceuticals | Ongoing |
| Jan 19, 2021 | An open label extension study of etripamil nasal spray in patients with paroxysmal supraventricular tachycardiaEtripamil (MSP-2017) | Milestone Pharmaceuticals | Closed |
| Sep 19, 2019 | Multi-centre, multi-national, open label, safety study of etripamil nasal spray for patients with paroxysmal supraventricular tachycardiaEtripamil (MSP-2017) | Milestone Pharmaceuticals | Closed |
| Jul 11, 2018 | Multi-centre, open-label, safety study of etripamil nasal spray in spontaneous episodes of paroxysmal supraventricular tachycardiaEtripamil (MSP-2017) | Milestone Pharmaceuticals | Closed |
| Jun 6, 2018 | Multi-centre, randomized, double-blind, placebo-controlled, efficacy, and safety study of etripamil nasal spray for the termination of spontaneous episodes of…Etripamil (MSP-2017) | Milestone Pharmaceuticals | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA